Marina Chiara Garassino to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Marina Chiara Garassino has written about Protein-Tyrosine Kinases.
Connection Strength
0.782
-
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Crit Rev Oncol Hematol. 2021 Apr; 160:103299.
Score: 0.175
-
Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report. Tumori. 2020 Dec; 106(6):NP41-NP45.
Score: 0.162
-
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
Score: 0.140
-
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5.
Score: 0.123
-
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6.
Score: 0.105
-
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020 10; 194:176-177.
Score: 0.041
-
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol. 2018; 249:63-89.
Score: 0.035